Literature DB >> 15797654

The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study.

Maya Koren-Michowitz1, Victor Dishy, Ronit Zaidenstein, Orit Yona, Sylvia Berman, Joshua Weissgarten, Ahuva Golik.   

Abstract

BACKGROUND: Thiazide diuretics and angiotensin-converting enzyme inhibitors can cause excessive urinary zinc (Zn) loss and Zn depletion. Thiazides may also induce magnesium (Mg) deficiency, which may exacerbate hypertension. Data on the effects of angiotensin receptor blockers on Zn and Mg homeostasis are scarce.
METHODS: Seventeen hypertensive patients were studied (ten men and seven women, age 50 +/- 3 years, blood pressure 158 +/- 5 / 95 +/- 3 mm Hg). Patients were treated with losartan 50 mg/day for 4 weeks followed by a fixed combination of 50 mg losartan and 12.5 mg hydrochlorothiazide for 4 weeks more. Blood and 24-h urine were collected at baseline and after each study period. Zinc and Mg levels were measured in serum, urine, and peripheral blood mononuclear cells. Nitric oxide metabolites were measured in urine.
RESULTS: Treatment with losartan resulted in a significant increase in the urinary Zn/creatinine ratio (from 0.020 +/- 0.004 microg/mg to 0.034 +/- 0.005 microg/mg, P = .02), which was further increased by the losartan/hydrochlorothiazide combination (from 0.034 +/- 0.005 microg/mg to 0.053 +/- 0.008 microg/mg, P = .03). Serum Zn levels were significantly decreased after losartan/hydrochlorothiazide (from 80.0 +/- 4.0 microg/dL at baseline to 74.0 +/- 3.0 microg/dL, P = .007). Peripheral blood mononuclear Zn concentrations were decreased also, but this was not statistically significant. Serum, urinary, and peripheral blood mononuclear Mg levels were not significantly affected by treatment. Nitric oxide urinary metabolites were unchanged throughout the study.
CONCLUSIONS: Treatment with losartan causes an increase in urinary Zn excretion and induces Zn deficiency in patients with hypertension. The addition of hydrochlorothiazide has an additive effect. Magnesium and nitric oxide metabolism are not affected by either treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797654     DOI: 10.1016/j.amjhyper.2004.09.019

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  13 in total

1.  Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism.

Authors:  Malay S Gandhi; Prajwal A Deshmukh; German Kamalov; Tieqiang Zhao; Wenyuan Zhao; Jonathan T Whaley; Jill R Tichy; Syamal K Bhattacharya; Robert A Ahokas; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2008-09       Impact factor: 3.105

Review 2.  Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives.

Authors:  Klaus K Witte; Andrew L Clark
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

3.  Clinical and echocardiographic correlates of serum copper and zinc in acute and chronic heart failure.

Authors:  Ioannis Alexanian; John Parissis; Dimitrios Farmakis; Sotirios Athanaselis; Loukas Pappas; Gerasimos Gavrielatos; Constantinos Mihas; Ioannis Paraskevaidis; Antonios Sideris; Dimitrios Kremastinos; Chaido Spiliopoulou; Maria Anastasiou-Nana; John Lekakis; Gerasimos Filippatos
Journal:  Clin Res Cardiol       Date:  2014-06-08       Impact factor: 5.460

4.  Nutrition in Pediatric Cardiomyopathy.

Authors:  Tracie L Miller; Daniela Neri; Jason Extein; Gabriel Somarriba; Nancy Strickman-Stein
Journal:  Prog Pediatr Cardiol       Date:  2007-11

Review 5.  Congestive heart failure is a systemic illness: a role for minerals and micronutrients.

Authors:  Shadwan Alsafwah; Stephen P Laguardia; Maximiliano Arroyo; Brian K Dockery; Syamal K Bhattacharya; Robert A Ahokas; Kevin P Newman
Journal:  Clin Med Res       Date:  2007-12

Review 6.  Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium.

Authors:  Karl T Weber; William B Weglicki; Robert U Simpson
Journal:  Cardiovasc Res       Date:  2008-10-03       Impact factor: 10.787

Review 7.  Targeting nitric oxide with drug therapy.

Authors:  R Preston Mason; John R Cockcroft
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

Review 8.  Zinc balance and medications commonly used in the management of heart failure.

Authors:  Natan Cohen; Ahuva Golik
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.654

Review 9.  Macro- and micronutrients in African-Americans with heart failure.

Authors:  Syamal K Bhattacharya; Robert A Ahokas; Laura D Carbone; Kevin P Newman; Ivan C Gerling; Yao Sun; Karl T Weber
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.654

10.  Sex-dependent, zinc-induced dephosphorylation of phospholamban by tissue-nonspecific alkaline phosphatase in the cardiac sarcomere.

Authors:  Yuan Wang; Nicole M Bishop; Douglas J Taatjes; Sonoko Narisawa; José Luis Millán; Bradley M Palmer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.